In Historic First, Massachusetts Attorney General Warns Gilead To Lower Cost Of Hep C Drug Or Face Lawsuit
Late in the summer of 2015, it was one solitary tweet by Hillary Clinton which, in retaliation to Martin Shkreli's infamous "price gouging", warned biotech and pharma companies to lower prices for their drugs, that was the catalyst which not only burst the biotech bubble but unleashed a chain of events that culminated with the worst year on record for momentum-gathering investors in alpha clothing such as Bill Ackman. It may have also top-ticked the overall market as it forced the best performing "momo" strategy of recent years to finally fizzle.